About Maltase-glucoamylase
Maltase-glucoamylase (MGAM) is a protein
from Homo sapiens identified by UniProt accession
O43451, 2753 residues long.
MolForge cross-references it against 0 known binders and
247 disease associations.
Target properties
| Protein name | Maltase-glucoamylase |
|---|
| UniProt accession | O43451 |
|---|
| Gene | MGAM |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2753 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (247)
Diseases linked to this target (Open Targets).
- type 2 diabetes mellitus · score 0.60
- diabetes mellitus · score 0.57
- chronic hepatitis C virus infection · score 0.40
- abnormal glucose tolerance · score 0.37
- type 1 diabetes mellitus · score 0.26
- metabolic disease · score 0.26
- gestational diabetes · score 0.26
- atherosclerosis · score 0.26
- metabolic syndrome · score 0.26
- hypertension · score 0.26
3D Structure (8)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (2753 residues)
MARKKLKKFT TLEIVLSVLL LVLFIISIVL IVLLAKESLK STAPDPGTTG TPDPGTTGTP DPGTTGTTHA RTTGPPDPGT TGTTPVSAEC PVVNELERIN CIPDQPPTKA TCDQRGCCWN PQGAVSVPWC YYSKNHSYHV EGNLVNTNAG FTARLKNLPS SPVFGSNVDN VLLTAEYQTS NRFHFKLTDQ TNNRFEVPHE HVQSFSGNAA ASLTYQVEIS RQPFSIKVTR RSNNRVLFDS SIGPLLFADQ FLQLSTRLPS TNVYGLGEHV HQQYRHDMNW KTWPIFNRDT TPNGNGTNLY GAQTFFLCLE DASGLSFGVF LMNSNAMEVV LQPAPAITYR TIGGILDFYV FLGNTPEQVV QEYLELIGRP ALPSYWALGF HLSRYEYGTL DNMREVVERN RAAQLPYDVQ HADIDYMDER RDFTYDSVDF KGFPEFVNEL HNNGQKLVII VDPAISNNSS SSKPYGPYDR GSDMKIWVNS SDGVTPLIGE VWPGQTVFPD YTNPNCAVWW TKEFELFHNQ VEFDGIWIDM NEVSNFVDGS VSGCSTNNLN NPPFTPRILD GYLFCKTLCM DAVQHWGKQY DIHNLYGYSM AVATAEAAKT VFPNKRSFIL TRSTFAGSGK FAAHWLGDNT ATWDDLRWSI PGVLEFNLFG IPMVGPDICG FALDTPEELC RRWMQLGAFY PFSRNHNGQG YKDQDPASFG ADSLLLNSSR HYLNIRYTLL PYLYTLFFRA HSRGDTVARP LLHEFYEDNS TWDVHQQFLW GPGLLITPVL DEGAEKVMAY VPDAVWYDYE TGSQVRWRKQ KVEMELPGDK IGLHLRGGYI FPTQQPNTTT LASRKNPLGL IIALDENKEA KGELFWDNGE TKDTVANKVY LLCEFSVTQN RLEVNISQST YKDPNNLAFN EIKILGTEEP SNVTVKHNGV PSQTSPTVTY DSNLKVAIIT DIDLLLGEAY TVEWSIKIRD EEKIDCYPDE NGASAENCTA RGCIWEASNS SGVPFCYFVN DLYSVSDVQY NSHGATADIS LKSSVYANAF PSTPVNPLRL DVTYHKNEML QFKIYDPNKN RYEVPVPLNI PSMPSSTPEG QLYDVLIKKN PFGIEIRRKS TGTIIWDSQL LGFTFSDMFI RISTRLPSKY LYGFGETEHR SYRRDLEWHT WGMFSRDQPP GYKKNSYGVH PYYMGLEEDG SAHGVLLLNS NAMDVTFQPL PALTYRTTGG VLDFYVFLGP TPELVTQQYT ELIGRPVMVP YWSLGFQLCR YGYQNDSEIA SLYDEMVAAQ IPYDVQYSDI DYMERQLDFT LSPKFAGFPA LINRMKADGM RVILILDPAI SGNETQPYPA FTRGVEDDVF IKYPNDGDIV WGKVWPDFPD VVVNGSLDWD SQVELYRAYV AFPDFFRNST AKWWKREIEE LYNNPQNPER SLKFDGMWID MNEPSSFVNG AVSPGCRDAS LNHPPYMPHL ESRDRGLSSK TLCMESQQIL PDGSLVQHYN VHNLYGWSQT RPTYEAVQEV TGQRGVVITR STFPSSGRWA GHWLGDNTAA WDQLKKSIIG MMEFSLFGIS YTGADICGFF QDAEYEMCVR WMQLGAFYPF SRNHNTIGTR RQDPVSWDAA FVNISRNVLQ TRYTLLPYLY TLMQKAHTEG VTVVRPLLHE FVSDQVTWDI DSQFLLGPAF LVSPVLERNA RNVTAYFPRA RWYDYYTGVD INARGEWKTL PAPLDHINLH VRGGYILPWQ EPALNTHLSR KNPLGLIIAL DENKEAKGEL FWDDGQTKDT VAKKVYLLCE FSVTQNHLEV TISQSTYKDP NNLAFNEIKI LGMEEPSNVT VKHNGVPSQT SPTVTYDSNL KVAIITDINL FLGEAYTVEW SIKIRDEEKI DCYPDENGDS AENCTARGCI WEASNSSGVP FCYFVNDLYS VSDVQYNSHG ATADISLKSS VHANAFPSTP VNPLRLDVTY HKNEMLQFKI YDPNNNRYEV PVPLNIPSVP SSTPEGQLYD VLIKKNPFGI EIRRKSTGTI IWDSQLLGFT FNDMFIRIST RLPSKYLYGF GETEHTSYRR DLEWHTWGMF SRDQPPGYKK NSYGVHPYYM GLEEDGSAHG VLLLNSNAMD VTFQPLPALT YRTTGGVLDF YVFLGPTPEL VTQQYTELIG RPVMVPYWSL GFQLCRYGYQ NDSEISSLYD EMVAAQIPYD VQYSDIDYME RQLDFTLSPK FAGFPALINR MKADGMRVIL ILDPAISGNE TQPYPAFTRG VEDDVFIKYP NDGDIVWGKV WPDFPDVVVN GSLDWDSQVE LYRAYVAFPD FFRNSTAKWW KREIEELYNN PQNPERSLKF DGMWIDMNEP SSFVNGAVSP GCRDASLNHP PYMPYLESRD RGLSSKTLCM ESQQILPDGS PVQHYNVHNL YGWSQTRPTY EAVQEVTGQR GVVITRSTFP SSGRWAGHWL GDNTAAWDQL KKSIIGMMEF SLFGISYTGA DICGFFQDAE YEMCVRWMQL GAFYPFSRNH NTIGTRRQDP VSWDVAFVNI SRTVLQTRYT LLPYLYTLMH KAHTEGVTVV RPLLHEFVSD QVTWDIDSQF LLGPAFLVSP VLERNARNVT AYFPRARWYD YYTGVDINAR GEWKTLPAPL DHINLHVRGG YILPWQEPAL NTHLSRQKFM GFKIALDDEG TAGGWLFWDD GQSIDTYGKG LYYLASFSAS QNTMQSHIIF NNYITGTNPL KLGYIEIWGV GSVPVTSVSI SVSGMVITPS FNNDPTTQVL SIDVTDRNIS LHNFTSLTWI STL
Explore Maltase-glucoamylase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets